NCT07123662撤回1 期
A Clinical Study on the Safety and Efficacy of γδ T Cells in Preventing Relapse After Allogeneic Transplantation in High-risk Acute Myeloid Leukemia Patients
Guangzhou Bio-gene Technology Co., Ltd0 个研究点目标入组 8 人开始时间: 2025年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 8
- 主要终点
- Incidence of Treatment-Emergent Adverse Events
研究概览
简要总结
This is a prospective, double-arm, single-center, randomized controlled single-blind clinical study
详细描述
This study is a prospective, single-center, two-arm, single-blind randomized controlled clinical trial to evaluate the safety and efficacy of γδ T cell infusion in preventing recurrence in patients with high-risk AML after allogeneic transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients voluntarily sign informed consent and are expected to complete the follow-up examination and treatment of the study procedures;
- •Age 18-65 years old (including cut-off value), gender is not limited;
- •AML patients have one of the high-risk factors for recurrence after allogeneic hematopoietic stem cell transplantation;
- •AML patients need to meet 30±5 days after the end of allogeneic transplant therapy;
- •The patient has recovered from the toxicity of the prior treatment, i.e., CTCAE toxicity grade < 2 (unless the abnormality is related to the tumor or is stable as judged by the investigator and has little impact on safety or efficacy);
- •ECOG performance status score of 0-3 points and expected survival greater than 3 months ;
- •Have appropriate organ function:
- •Alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN);
- •Aspartate aminotransferase (AST) ≤ 3 times ULN;
- •Total bilirubin ≤1.5 times ULN;
- •Serum creatinine ≤1.5 times ULN or creatinine clearance ≥ 60 mL/min;
- •Hemoglobin ≥ 50g/L (must not have received transfusion support within 7 days prior to laboratory tests);
- •Room oxygen saturation ≥92%;
- •Left ventricular ejection fraction (LVEF) ≥ 45%, echocardiography confirmed no pericardial effusion, no clinically significant ECG findings;
- •Without clinically significant pleural effusion;
排除标准
- •Other malignant tumors within 3 years prior to screening, except for adequately treated carcinoma in situ of the cervix, papillary carcinoma of the thyroid, basal cell or squamous epithelial cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection;
- •Patients have a severe allergic history;
- •The patient has severe heart disease;
- •The patient has severe respiratory system disease;
- •Those with grade III~IV acute GVHD or extensive chronic GVHD;
- •Patients who are using (or willing to use) other maintenance therapy drugs after hematopoietic stem cell transplantation and have proven that this maintenance therapy drug is not conducive to the persistence of γδ T cells in vivo;
- •Active neurological autoimmune or inflammatory diseases, amyotrophic lateral sclerosis (ALS), and clinically significant active cerebrovascular disease;
- •Patients with severe mental illness;
- •Alcoholics or those with a history of drug abuse;
- •Clinically significant active cerebrovascular disease;
- •Those who have participated in other clinical studies within 1 month before screening and have not interfered with the safety and efficacy of this study drug as assessed by the investigator are allowed to be included in the study, such as non-interventional observational studies;
- •Pregnant or lactating women, and female subjects who plan to become pregnant within 1 year after cell reinfusion or male subjects whose partners plan to become pregnant within 1 year after their cell reinfusion;
- •Any unsuitable to participate in this trial judged by the investigator.
研究组 & 干预措施
Standard prophylactic treatment
Other
Control group: High-risk AML received only standard prophylactic treatment after allogeneic transplantation
干预措施: Standard prophylactic treatment (Other)
Gamma-Delta T cell injection
Experimental
Experimental group: Received γδT infusion after high-risk AML allogene transplantation standard prophylactic treatment.
干预措施: Gamma-Delta T cell injection (Biological)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events
时间窗: Up to 12 months.
Count the Incidence of adverse events.
次要结局
- Levels of peripheral blood γδ T cells after infusion（PK）(Up to 12 months.)
- Concentration of Cytokine after Infusion (PD)(Up to 12 months.)
研究者
相似试验
已完成
2 期
Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar FasciitisPlantar FasciitisNCT03137407Revance Therapeutics, Inc.59
终止
2 期
DaxibotulinumtoxinA for Injection for the Management of Plantar FasciitisPlantar FasciitisNCT02973269Revance Therapeutics, Inc.7
已完成
1 期
Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male VolunteersHealthySafetyNCT03694041Aptabio Therapeutics, Inc.88
已完成
不适用
A Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract)Body Weight in the Overweight and Obese Class - I PopulationNCT05711784NovoBliss Research Pvt Ltd66
Unknown
2 期
A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine RegimenMetastatic Pancreatic CancerNCT05138159Fudan University10